In malignant diseases, such as myeloma, osteolytic bone metastases of prostate and breast cancer, enhanced expression of RANKL by tumor cells and tumor-induced increase of the RANKL/OPG ratio in bone microenvironment can be observed (35). The gene discussed is TNFRSF11B; the disease is neoplasm.